Improved magnetomotive embolization for hepatocellular carcinoma - cancer is the 2ND leading cause of death in the united states (US) and accounts for 1 of every 4 deaths

Active Grant Awarded

Award ID
R43CA310649
Recipient
Awarding agency
Obligated
$405,753

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 22% complete
Place of performance
St. Louis, MO 63110, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded Unandup, LLC $405,753 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395), to fund improved magnetomotive embolization for hepatocellular carcinoma. The award is a Phase I Small Business Innovation Research grant with an ultimate completion date of August 31, 2027, and the place of performance is St. Louis, MO 63110, USA.

The source describes catheter-directed trans-arterial embolization as the gold standard of care for intermediate-stage hepatocellular carcinoma, but it notes that the procedure remains unstandardized in particle size and type, chemotherapeutic agent choice and dose, and the interval between procedures. It also cites a survival benefit of only 4 months and safety concerns, including embolization of unintended territories. The funded work is the magnetomotive embolization technology that the source frames as an improvement on this procedure.

Unandup is a for-profit medical device technology company headquartered in St. Louis, Missouri, and it is the sole recipient identified for this award. The source identifies no sub-recipients.

Description

More than 600,000 americans will DIE of cancer in 2018, with annual US cancer-care expenditures reaching $156B by 2020, and more than 10M cancer-related deaths occur annually. While chemotherapy is effective, several cancer subtypes (including liver cancer) are associated with a very low 5-year survival rate of less than 20%. In addition, only a small proportion of cancer patients is eligible for tumor resection and organ transplant. Hepatocellular carcinoma is the most common form of primary liver cancer, with over 500,000 new diagnoses each year and a 5-year survival rate of less than 18%. IT remains the 6TH most common cancer worldwide and the 3RD most common cause of cancer-related deaths. Unlike other cancers, the death rate for liver cancer has increased over the last 30 years. In general, chemotherapeutic treatment has shown limited effectiveness, with response rates less than 20% and survival less than one-year. One of the few options available to those diagnosed with hepatocellular carcinoma is catheter-directed trans-arterial embolization (with and without chemoembolization), which is the gold standard of care for those diagnosed with intermediate- stage carcinoma. However, despite the procedure's use for over two decades, IT remains largely unstandardized, with variations in the size and type of embolizing particles, choice and dose of chemotherapeutic agent, and the time interval between procedures. Though effective, the procedure's benefit is modest in that the survival improvement is only 4 months, and the treatment is associated with safety concerns, including embolization of unintended territories. The procedure's efficacy is hampered by the tumor's complex hemodynamics and tortuous vasculature, resulting in regions which cannot be reliably and thoroughly occluded. IT is generally believed that patient outcomes would be improved if physicians could more completely embolize the tumor's vascular network. If this were achieved, the tumor would be better starved of blood flow and chemotherapeutic agents could be more effectively delivered. UN & up has developed a breakthrough technology that enables the physician to directly control and improve the delivery of magnetic embolization beads into and throughout a tumor's vasculature. By creating unique magnetic embolization beads, which will be safe in an MR environment, and using the company's novel magnet system which generates selective magnetic instabilities at the tumor, embolization beads can be controlled in a way not otherwise possible. The result is a technology with the potential to provide substantially more effective and safer liver tumor embolizations for hepatocellular carcinoma patients. In the phase I effort, the company will 1) formulate the prototype magnetic embolization beads, 2) assess in vitro model efficacy and MR safety, and 3) assess in vivo efficacy in a rabbit tumor model. An FDA meeting in planned is advance of a phase II proposal.

Quick answers

Who received award R43CA310649?

R43CA310649 was awarded to Unandup, LLC by National Cancer Institute (National Institutes of Health) on September 1, 2026.

How much is award R43CA310649 worth?

$405,753 has been obligated on R43CA310649.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award